FreeCME

Pulmonary Arterial Hypertension in Connective Tissue Disease: Improving Awareness, Screening, and Management

CME: 1.0

March 31, 2021
/ Print / Reprints /
| Share More
/ Text Size+
PROGRAM OVERVIEW:
Thanks to improvements in therapies and management, survival for patients with pulmonary arterial hypertension (PAH) has improved over the last 20 years. Unfortunately, patients with PAH and connective tissue disease (CTD)—especially systemic sclerosis—have not matched these outcomes. What is your role in closing this gap, even if you are not in a pulmonary hypertension specialty center? In this video roundtable, three experts in rheumatology and pulmonary medicine give you front-row access to their discussions on how rheumatology, pulmonology, and cardiology physicians, NPs, and PAs can collaborate to recognize and manage PAH early in this crucial patient population.
In Partnership With the Association of Pulmonary Advanced Practice Providers
  
In Partnership With the Society of Physician Assistants in Rheumatology

 
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be better able to:  
After completing this activity, participants should be better able to:
  • Identify the symptoms and signs of CTD-PAH and the screening tools needed to refer patients for further evaluation and prompt initiation of treatment
  • Describe current recommendations for the management of PAH and how they should be tailored to patients with CTD

Post a comment to this article